Shire PLC (LON:SHP) had its price objective trimmed by HSBC Holdings PLC from GBX 4,050 ($53.27) to GBX 3,800 ($49.98) in a research report sent to investors on Tuesday morning. The firm currently has a hold rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on SHP. Liberum Capital restated a buy rating and set a GBX 4,200 ($55.24) target price on shares of Shire PLC in a research note on Monday, November 20th. Citigroup Inc. restated a buy rating and set a GBX 6,300 ($82.86) target price on shares of Shire PLC in a research note on Tuesday, August 22nd. J P Morgan Chase & Co restated an overweight rating on shares of Shire PLC in a research note on Tuesday. Royal Bank Of Canada restated an outperform rating on shares of Shire PLC in a research note on Friday, November 17th. Finally, Shore Capital restated a buy rating on shares of Shire PLC in a research note on Tuesday, August 15th. Four investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of GBX 5,250 ($69.05).

Shire PLC (SHP) opened at GBX 3,711 ($48.81) on Tuesday. Shire PLC has a one year low of GBX 3,435.50 ($45.19) and a one year high of GBX 5,067 ($66.64).

In other news, insider Anne Minto bought 190 shares of the firm’s stock in a transaction on Friday, September 29th. The shares were bought at an average price of GBX 3,785 ($49.78) per share, for a total transaction of £7,191.50 ($9,458.77).

TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/hsbc-holdings-plc-lowers-shire-plc-shp-price-target-to-gbx-3800/1725025.html.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (LON:SHP)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.